

Evolocumab (PCSK9i): A bride for the old faithful statin?

How low will you really go with LDL?

Are there people who do not respond to PCSK9 inhibitors?

When should PCSK9 inhibitors be first-line?

Is there a difference between PCSK9 inhibitors?

What is the role of PCSK9 inhibitors for non-LDL dyslipidaemia?

Date: 6 October 2021, Wednesday

Time: 6 - 7pm (Singapore Time, UTC+8)

[Register Now](#)

Speaker



Prof Heinz Drexel
Professor
Vorarlberg Institute for Vascular Investigation and Treatment
Austria

Panellists



Prof Alberto J Lorenzatti
Co-Director, Instituto Médico DAMIC
Fundación Rusculleda de Investigación en Medicina
Argentina



Prof Krzysztof Filipiak
Professor of Cardiology
Medical University of Warsaw
Poland

Moderators



Franco Cheng
Pharmacist
Department of Pharmacy
Yan Chai Hospital, Hospital Authority
Hong Kong



Assoc Prof Doreen Tan
Cardiology Specialist Pharmacist
Department of Pharmacy
National University of Singapore
Singapore

Endorsed by:



Asian Pacific Society of Cardiology



Singapore Cardiac Society

Accredited by:



EBAC®

European Board for Accreditation in Cardiology

In collaboration with:



Managed by:



Across Continents. Beyond Conventions.